share_log

S-1: General form for registration of securities under the Securities Act of 1933

S-1: General form for registration of securities under the Securities Act of 1933

S-1:證券上市註冊聲明
美股SEC公告 ·  11/16 05:21

牛牛AI助理已提取核心訊息

180 Life Sciences Corp. has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) on November 15, 2024, for the issuance of common stock shares. The registration statement includes a prospectus for the resale of up to 1,900,138 shares of common stock by the selling stockholder, Armistice Capital, LLC. These shares are issuable upon the exercise of warrants acquired by the selling stockholder under an inducement agreement. The company will not receive any proceeds from the sale of shares by the selling stockholder. However, if all warrants are exercised for cash, 180 Life Sciences may receive up to approximately $2,850,207, which it intends to use for operationalizing and developing its recently acquired Technology Gaming Platform, and for general corporate and legal expenses. The common stock is traded on the Nasdaq Capital Market under the symbol 'ATNF'. The company has also detailed its capital structure, including its authorized common and preferred stock, and outlined certain anti-takeover provisions in its certificate of incorporation and bylaws.
180 Life Sciences Corp. has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) on November 15, 2024, for the issuance of common stock shares. The registration statement includes a prospectus for the resale of up to 1,900,138 shares of common stock by the selling stockholder, Armistice Capital, LLC. These shares are issuable upon the exercise of warrants acquired by the selling stockholder under an inducement agreement. The company will not receive any proceeds from the sale of shares by the selling stockholder. However, if all warrants are exercised for cash, 180 Life Sciences may receive up to approximately $2,850,207, which it intends to use for operationalizing and developing its recently acquired Technology Gaming Platform, and for general corporate and legal expenses. The common stock is traded on the Nasdaq Capital Market under the symbol 'ATNF'. The company has also detailed its capital structure, including its authorized common and preferred stock, and outlined certain anti-takeover provisions in its certificate of incorporation and bylaws.
180 life sciences公司已於2024年11月15日向美國證券交易委員會(SEC)提交了註冊聲明,用於發行普通股股份。該註冊聲明包括了由賣方股東Armistice Capital,LLC擁有的高達1,900,138股普通股的再銷售概要。這些股份可通過賣方股東根據誘因協議獲得的認股權行使而發行。公司不會從賣方股東出售股份中獲得任何收入。但是,如果所有認股權都以現金行使,180 life sciences可能最多收取約$2,850,207,其打算用於運營和開發其最近獲得的科技遊戲平台,以及一般公司和法律費用。這些普通股在納斯達克資本市場以"ATNF"標的進行交易。該公司還詳細說明了其資本結構,包括其授權的普通股和優先股,並概述了其公司章程和公司法的某些防禦收購規定。
180 life sciences公司已於2024年11月15日向美國證券交易委員會(SEC)提交了註冊聲明,用於發行普通股股份。該註冊聲明包括了由賣方股東Armistice Capital,LLC擁有的高達1,900,138股普通股的再銷售概要。這些股份可通過賣方股東根據誘因協議獲得的認股權行使而發行。公司不會從賣方股東出售股份中獲得任何收入。但是,如果所有認股權都以現金行使,180 life sciences可能最多收取約$2,850,207,其打算用於運營和開發其最近獲得的科技遊戲平台,以及一般公司和法律費用。這些普通股在納斯達克資本市場以"ATNF"標的進行交易。該公司還詳細說明了其資本結構,包括其授權的普通股和優先股,並概述了其公司章程和公司法的某些防禦收購規定。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。